Regulus Considers miR-21 Drug as Next Clinical Candidate amid Positive Alport Data | GenomeWeb

Regulus Therapeutics this week released new preclinical data showing that microRNA-21 is implicated in the fibrotic kidney condition Alport syndrome and indicated that the program could likely yield its next clinical candidate.

The company also released its third quarter financial results, which included a drop in its net loss amid increased revenues, and disclosed that it is nearing the completion of negotiations with partner Sanofi regarding taking a larger role in the miR-21 effort.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.